Esperion Posts Big Loss, But Drug Test Results Promising
Esperion Therapeutics Inc., (Nasdaq: ESPR), the pharmaceutical company developing promising new cholesterol therapies, reported a big loss for 2013 -- but continued promising clincal trial results.
